NBCA/X
May 8, 2026, 06:03
Risk-Stratified HRT Use Following VTE – NBCA
NBCA shared a post on X:
“The blanket ‘no HRT after VTE’ approach is being challenged — and Dr. Cromwell is leading that conversation.
Her focus: which patient, which formulation, which risk level.
Route matters — transdermal > oral.
Thrombophilia and provocation status are critical.
Progestogen choice matters.
Hematology plus gynecology must collaborate.
Join Dr. Cromwell at NBCA’s May PEP Talk: Women and Blood Clots.
May 12 | 7 PM ET.”
Stay updated with Hemostasis Today.
-
Nov 10, 2026, 11:11Roberta Gualtierotti: Oral Signs of Systemic Immune-Mediated Diseases
-
Nov 10, 2026, 11:08Tim Brümmendorf: FlowFISH in New ASH Guidelines for Aplastic Anemia
-
Nov 10, 2026, 11:01Sophia Delicou: Bronze Award for Hippokration’s Hemoglobinopathy Centre
-
Nov 10, 2026, 10:16Building Future Leaders in Transfusion Medicine – TRAM Leadership Program
-
Nov 10, 2026, 10:04Paolo Zamboni: A New Generation of Vascular Surgeons Graduates
-
Nov 10, 2026, 09:59Jessica Garcia: More Than a Walk – A Community United for Bleeding Disorders
-
Nov 10, 2026, 09:51Heghine Khachatryan: Balancing Thrombosis and Bleeding Risks in Acute Leukemia
-
Nov 10, 2026, 09:38How Hydroxyurea Affects Ovarian Reserve in Girls and Women with SCD – ASH Education
-
Nov 10, 2026, 08:43Rufiga Shari Abidin: Multi Organ Complications Detailed in COVID 19 Vaccine Adverse Event Study